Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 43.54% |
| 2 | Technology | 19.7% |
| 3 | Financials | 7.47% |
| 4 | Consumer Discretionary | 6.7% |
| 5 | Communication Services | 6.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
801
BridgeBio Pharma
BBIO
$13.1B
| $47.6M | 0.01% |
622,575
-96,873
| -13% | -$6.36M |
2019 Q2
26 quarters
|
|
802
Williams-Sonoma
WSM
$27.4B
| $47.5M | 0.01% |
265,924
-45,203
| -15% | -$8.47M |
2013 Q2
50 quarters
|
|
803
Twilio
TWLO
$45.2B
| $47.5M | 0.01% |
333,829
+7,187
| +2% | +$890K |
2016 Q3
37 quarters
|
|
804
Allegion
ALLE
$13.1B
| $47.3M | 0.01% |
296,962
-134,779
| -31% | -$22.5M |
2013 Q4
48 quarters
|
|
805
PUT
Intuit
INTU
$75.1B
| $47.1M | 0.01% |
71,100
+60,000
| +541% | +$39.6M |
2024 Q4
4 quarters
|
|
806
Jacobs Solutions
J
$16.2B
| $47M | 0.01% |
354,780
+109,988
| +45% | +$16.1M |
2013 Q2
50 quarters
|
|
807
Lamb Weston
LW
$5.99B
| $46.9M | 0.01% |
1,120,722
+460,091
| +70% | +$27.1M |
2016 Q4
36 quarters
|
|
808
Cloudflare
NET
$124B
| $46.7M | 0.01% |
237,035
+52,134
| +28% | +$11M |
2022 Q1
15 quarters
|
|
809
Amcor
AMCR
$19.3B
| $46.7M | 0.01% |
1,119,875
-393,157
| -26% | -$16.2M |
2019 Q2
26 quarters
|
|
|
B
810
Barrick Mining
B
$66.2B
| $46.6M | 0.01% |
1,070,031
-1,588,542
| -60% | -$59.6M |
2013 Q2
50 quarters
|
|
811
Coherent
COHR
$66B
| $46.6M | 0.01% |
252,299
+96,236
| +62% | +$14.4M |
2013 Q2
50 quarters
|
|
812
Best Buy
BBY
$18.4B
| $46.5M | 0.01% |
695,423
+64,175
| +10% | +$4.9M |
2013 Q2
50 quarters
|
|
813
International Flavors & Fragrances
IFF
$21B
| $46.3M | 0.01% |
687,775
-311,487
| -31% | -$20.2M |
2013 Q2
50 quarters
|
|
814
Grab
GRAB
$12.6B
| $46.3M | 0.01% |
9,281,133
-1,794,340
| -16% | -$9.91M |
2022 Q1
15 quarters
|
|
815
Okta
OKTA
$37B
| $46.3M | 0.01% |
535,394
-82,572
| -13% | -$7.21M |
2017 Q2
34 quarters
|
|
816
CALL
ExxonMobil
XOM
$674B
| $46.3M | 0.01% |
384,500
-1,753,100
| -82% | -$203M |
2022 Q4
12 quarters
|
|
817
PUT
Norwegian Cruise Line
NCLH
$6.95B
| $46.1M | 0.01% |
2,064,400
+1,564,400
| +313% | +$33M |
2024 Q3
5 quarters
|
|
818
CALL
Datadog
DDOG
$99.5B
| $46M | 0.01% |
338,400
+46,000
| +16% | +$7.27M |
2023 Q4
8 quarters
|
|
819
Royal Bank of Canada
RY
$271B
| $45.9M | 0.01% |
269,032
+139,980
| +108% | +$21.5M |
2013 Q2
50 quarters
|
|
820
Sabra Healthcare REIT
SBRA
$4.89B
| $45.9M | 0.01% |
2,421,192
+994,474
| +70% | +$18.4M |
2013 Q2
50 quarters
|
|
821
Crown Holdings
CCK
$11.5B
| $45.8M | 0.01% |
445,160
-51,287
| -10% | -$5M |
2013 Q2
50 quarters
|
|
822
Zebra Technologies
ZBRA
$17.8B
| $45.5M | 0.01% |
187,544
-8,386
| -4% | -$2.24M |
2013 Q2
50 quarters
|
|
823
Moderna
MRNA
$75.9B
| $45.5M | 0.01% |
1,542,457
-473,371
| -23% | -$12.9M |
2019 Q1
27 quarters
|
|
824
CALL
CVS Health
CVS
$111B
| $45.3M | 0.01% |
571,400
-384,000
| -40% | -$30.3M |
2023 Q3
9 quarters
|
|
825
Church & Dwight Co
CHD
$22.4B
| $45.3M | 0.01% |
540,486
-157,229
| -23% | -$13.4M |
2013 Q2
50 quarters
|
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $23.5B in Q4 2025, closing 641 positions and reducing 1,714 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 44% of assets, down from 44% a quarter earlier, followed by Technology and Financials.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.